瑞波西汀与氟西汀治疗首发抑郁症对照研究

Comparative Study of Reboxetine with Fluoxitine in the Treatmet of First-episode Depression

目的比较甲磺酸瑞波西汀和盐酸氟西汀治疗首发抑郁症的疗效和安全性。方法采用随机对照研究,将54例首发抑郁症患者随机分为瑞波西汀组27例和氟西汀组27例,治疗6周。用汉密尔顿抑郁量表(HAMD17)和汉密尔顿焦虑量表(HAMA)评定症状严重程度,用副反应量表(TESS)评定安全性。结果瑞波西汀组有效率为74.0%,氟西汀组有效率为69.2%,两组疗效相当,但在第4周、第6周末瑞波西汀组焦虑/躯体化因子分和HAMA评分下降较氟西汀组快,两组间比较差异有统计学意义(P<0.05)。在安全性方面,瑞波西汀组副反应较少,程度轻,且都能耐受。结论瑞波西汀治疗首发抑郁症患者疗效确切,能有效改善抑郁症伴发的焦虑症状,副反应较少,程度轻。

OBJECTIVE To study the efficacy and safety of reboxetine in the treatment of patients with first-episode depression.METHODS 54 patients with first-episode depression were randomly assigned to reboxetine groop and fluoxitine group.27 patients reseived reboxetine while 27 patients were treated with fluoxitine for 6 weeks.The efficacy was assessed with HAMD17 and HAMA and adverse reactions with TESS.RESULTS The effective rate of the reboxetine groop is 74.0%.The effective rate of the fluoxitine groop is 69.2%.There is no difference between the two groups in efficacy.While the scores of the somatization facts and HAMA of reboxetine groop significantly decreased than fluoxitine group at the end of the 4 weeks and 6 weeks.There are difference between the two groups（P0.05）.The adverse reactions are low and light in two groups.CONCLUSIONS Reboxetine is a effective and safe drug in the treatment of first-episode depression patients especially with anxiety symptoms.